Abeona Therapeutics Inc. (NASDAQ:ABEO) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a research note issued to investors on Wednesday. The brokerage currently has a $18.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target would indicate a potential upside of 11.46% from the stock’s previous close.

According to Zacks, “Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. “

Other analysts have also recently issued research reports about the stock. BidaskClub cut shares of Abeona Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 27th. HC Wainwright restated a “buy” rating and set a $30.00 price objective (up previously from $20.00) on shares of Abeona Therapeutics in a research report on Monday, October 16th. Citigroup Inc. started coverage on shares of Abeona Therapeutics in a research report on Tuesday, October 10th. They set a “buy” rating and a $32.00 price objective on the stock. Cantor Fitzgerald restated a “buy” rating and set a $21.00 price objective on shares of Abeona Therapeutics in a research report on Friday, October 6th. Finally, Maxim Group set a $17.00 price objective on shares of Abeona Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 29th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Abeona Therapeutics currently has an average rating of “Buy” and an average price target of $26.10.

Shares of Abeona Therapeutics (ABEO) opened at $16.15 on Wednesday. Abeona Therapeutics has a 52-week low of $4.05 and a 52-week high of $22.75.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.05. The firm had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.22 million. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. analysts forecast that Abeona Therapeutics will post -0.66 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/zacks-investment-research-upgrades-abeona-therapeutics-inc-abeo-to-buy/1722792.html.

Large investors have recently modified their holdings of the stock. State of Wisconsin Investment Board purchased a new position in Abeona Therapeutics in the 2nd quarter worth $122,000. Rhumbline Advisers purchased a new position in Abeona Therapeutics in the 2nd quarter worth $190,000. Wells Fargo & Company MN raised its position in Abeona Therapeutics by 3,421.8% in the 3rd quarter. Wells Fargo & Company MN now owns 35,218 shares of the biopharmaceutical company’s stock worth $600,000 after purchasing an additional 34,218 shares during the period. Family Management Corp raised its position in Abeona Therapeutics by 50.0% in the 3rd quarter. Family Management Corp now owns 36,000 shares of the biopharmaceutical company’s stock worth $614,000 after purchasing an additional 12,000 shares during the period. Finally, Schwab Charles Investment Management Inc. purchased a new position in Abeona Therapeutics in the 2nd quarter worth $264,000. Institutional investors own 36.34% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.